<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
SCHEDULE 13G
(RULE 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED
PURSUANT TO 13d-2(b)
(AMENDMENT NO. __)(1)
AUTOIMMUNE INC.
---------------
(Name of Issuer)
COMMON STOCK
------------
(Title of Class of Securities)
052776 10 1
-----------
(CUSIP Number)
NOVEMBER 1, 1999
----------------
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
/ / Rule 13d-1(b)
/X/ Rule 13d-1(c)
/ / Rule 13d-1(d)
- ------------------------
(1) The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which would
alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not
be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, SEE the
NOTES).
<PAGE>
- ------------------------------ ------------------------------
CUSIP NO. 052776 10 1 13G PAGE 2 OF 7 PAGES
- ------------------------------ ------------------------------
- -------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON:
BIOTECHNOLOGY VALUE FUND, L.P.
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY):
- -------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) /X/ (b) / /
- -------------------------------------------------------------------------------
3 SEC USE ONLY
- -------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
DELAWARE
- -------------------------------------------------------------------------------
NUMBER (5) SOLE VOTING POWER
OF 0
SHARES ----------------------------------------------------
BENEFICIALLY (6) SHARED VOTING POWER
OWNED BY 836,625
EACH ----------------------------------------------------
REPORTING (7) SOLE DISPOSITIVE POWER
PERSON 0
WITH ----------------------------------------------------
(8) SHARED DISPOSITIVE POWER
836,625
- -------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON
836,625
- -------------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES* / /
- -------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
5.0%
- -------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON*
PN
- -------------------------------------------------------------------------------
* SEE INSTRUCTIONS BEFORE FILLING OUT!
<PAGE>
- ------------------------------ ------------------------------
CUSIP NO. 052776 10 1 13G PAGE 3 OF 7 PAGES
- ------------------------------ ------------------------------
- -------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON:
BVF PARTNERS L.P.
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY):
- -------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) /X/ (b) / /
- -------------------------------------------------------------------------------
3 SEC USE ONLY
- -------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
DELAWARE
- -------------------------------------------------------------------------------
NUMBER (5) SOLE VOTING POWER
OF 0
SHARES ----------------------------------------------------
BENEFICIALLY (6) SHARED VOTING POWER
OWNED BY 1,476,100
EACH ----------------------------------------------------
REPORTING (7) SOLE DISPOSITIVE POWER
PERSON 0
WITH ----------------------------------------------------
(8) SHARED DISPOSITIVE POWER
1,476,100
- -------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON
1,476,100
- -------------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES* / /
- -------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
8.9%
- -------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON*
PN
- -------------------------------------------------------------------------------
* SEE INSTRUCTIONS BEFORE FILLING OUT!
<PAGE>
- ------------------------------ ------------------------------
CUSIP NO. 052776 10 1 13G PAGE 4 OF 7 PAGES
- ------------------------------ ------------------------------
- -------------------------------------------------------------------------------
1 NAME OF REPORTING PERSONS
BVF INC.
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
- -------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) /X/ (b) / /
- -------------------------------------------------------------------------------
3 SEC USE ONLY
- -------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
DELAWARE
- -------------------------------------------------------------------------------
NUMBER (5) SOLE VOTING POWER
OF 0
SHARES ----------------------------------------------------
BENEFICIALLY (6) SHARED VOTING POWER
OWNED BY 1,476,100
EACH ----------------------------------------------------
REPORTING (7) SOLE DISPOSITIVE POWER
PERSON 0
WITH ----------------------------------------------------
(8) SHARED DISPOSITIVE POWER
1,476,100
- -------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON
1,476,100
- -------------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES*
- -------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
8.9%
- -------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON*
IA, CO
- -------------------------------------------------------------------------------
* SEE INSTRUCTIONS BEFORE FILLING OUT!
<PAGE>
- ------------------------------ ------------------------------
CUSIP NO. 052776 10 1 13G PAGE 5 OF 7 PAGES
- ------------------------------ ------------------------------
ITEM 1(a). NAME OF ISSUER:
Autoimmune, Inc. ("Autoimmune")
ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
128 Spring Street
Lexington, Massachusetts 02173
ITEM 2(a). NAME OF PERSON FILING:
This schedule is being filed on behalf of the following
persons*:
(i) Biotechnology Value Fund, L.P. ("BVF")
(ii) BVF Partners L.P. ("Partners")
(iii) BVF Inc. ("BVF Inc.")
* Attached as Exhibit A is a copy of an agreement among
the persons filing (as specified hereinabove) that
this Schedule 13G is being filed on behalf of each of
them.
ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE:
The principal business office of the persons
comprising the group filing this Schedule 13G is located at 227 West Monroe
Street, Suite 4800, Chicago, Illinois, 60606.
ITEM 2(c). CITIZENSHIP:
BVF: a Delaware limited partnership
Partners: a Delaware limited partnership
BVF Inc.: a Delaware corporation
ITEM 2(d). TITLE OF CLASS OF SECURITIES:
Common Stock.
ITEM 2(e). CUSIP NUMBER:
052776 10 1
ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO RULE 13d-1(c),
CHECK THIS BOX: /X/
<PAGE>
- ------------------------------ ------------------------------
CUSIP NO. 052776 10 1 13G PAGE 6 OF 7 PAGES
- ------------------------------ ------------------------------
ITEM 4. OWNERSHIP:
The information in items 1 and 5 through 11 on the
cover pages (pp. 2 - 5) on Schedule 13G is hereby incorporated by
reference.
ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
If this statement is being filed to report the fact that as
of the date hereof the reporting person has ceased to be the beneficial owner
of more than five percent of the class of securities check the following. / /
ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF
ANOTHER PERSON:
BVF shares voting and dispositive power over the shares of
the common stock it beneficially owns with Partners. Partners and BVF Inc.
share voting and dispositive power over the shares of the common stock they
beneficially own with, in addition to BVF, certain managed accounts on whose
behalf Partners, as investment manager, purchased such shares. None of the
managed accounts individually owns more than 5% of the common stock of
Autoimmune.
ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY
WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE
PARENT HOLDING COMPANY:
Not applicable.
ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF A
GROUP:
Not applicable.
ITEM 9. NOTICE OF DISSOLUTION OF GROUP:
Not applicable.
<PAGE>
- ------------------------------ ------------------------------
CUSIP NO. 052776 10 1 13G PAGE 7 OF 7 PAGES
- ------------------------------ ------------------------------
ITEM 10. CERTIFICATION
By signing below I certify that, to the best of my
knowledge and belief, the securities referred to above were not acquired and
are not held for the purpose of or with the effect of changing or influencing
the control of the issuer of the securities and were not acquired and are not
held in connection with or as a participant in any transaction having that
purpose or effect.
After reasonable inquiry and to the best of my knowledge
and belief, I certify that the information set forth in this statement is
true, complete and correct.
Dated: November 8, 1999
BIOTECHNOLOGY VALUE FUND, L.P.
By: BVF Partners L.P., its general partner
By: BVF Inc., its general partner
By: /s/ Mark N. Lampert
----------------------
Mark N. Lampert
President
BVF PARTNERS L.P.
By: BVF Inc., its general partner
By: /s/ Mark N. Lampert
---------------------
Mark N. Lampert
President
BVF INC.
By: /s/ Mark N. Lampert
---------------------
Mark N. Lampert
President
<PAGE>
EXHIBIT A
AGREEMENT REGARDING JOINT FILING
The undersigned, Biotechnology Value Fund, L.P., a Delaware limited
partnership, and BVF Partners L.P., a Delaware limited partnership, and BVF
Inc., a Delaware corporation, hereby agree and acknowledge that the information
required by Schedule 13G, to which this Agreement is attached as an exhibit, is
filed on behalf of each of them. The undersigned further agree that any
amendments or supplements thereto shall also be filed on behalf of each of them.
Dated: November 8, 1999
BIOTECHNOLOGY VALUE FUND, L.P.
By: BVF Partners L.P., its general partner
By: BVF Inc., its general partner
By: /s/ Mark N. Lampert
----------------------
Mark N. Lampert
President
BVF PARTNERS L.P.
By: BVF Inc., its general partner
By: /s/ Mark N. Lampert
---------------------
Mark N. Lampert
President
BVF INC.
By: /s/ Mark N. Lampert
---------------------
Mark N. Lampert
President
